Bravelle approval (correction)
Executive Summary
Ferring's Bravelle (urofollitropin) is the fourth human-derived gonadotropin on the market, following Serono's Fertinex (urofollitropin) and Pergonal (menotropins), and Ferring's Repronex (menotropins). Bravelle and Fertinex are follitropins, while Pergonal and Repronex are not (1"The Pink Sheet" May 13, In Brief)...
You may also be interested in...
Ferring Bravelle approved
Ferring's Bravelle (urofollitropin) clears FDA May 6 for use in conjunction with human chorionic gonadotropin "for ovulation induction in patients who have previously received pituitary suppression." The intramuscular/subcutaneous injectable will be the third human-derived follitropin on the market, joining Serono's Fertinex (urofollitropin) and Pergonal (menotropins). Bravelle will be available in mid-May, Ferring said. The company has a pending NDA for use of Bravelle in in-vitro fertilization...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.